Jim Cramer says he was recruited for Johnson & Johnson Covid-19 vaccine trial last week
CNBC's Jim Cramer, Carl Quintanilla and David Faber discuss Johnson & Johnson's coronavirus vaccine and whether the company's vaccine will be as effective as the other vaccines that will be available to the public. Subscribe to CNBC PRO for access to investor and analyst insights: https://cnb.cx/2Vtntx6
CNBC’s Jim Cramer said Tuesday that Wall Street is gaining confidence in the potential rollout of a coronavirus vaccine in the U.S., suggesting investors believe the serious challenges caused by the pandemic could soon be behind the country.
“The market is very prescient. I think the market has been going up because we’re starting to realize this may be — for all intents and purposes in America, not in the rest of the world — over in the second quarter of 2021,” Cramer said on “Squawk on the Street.”
The stock market had a very strong November, despite uncertainty caused by President Donald Trump’s challenges to the election and a worsening Covid-19 outbreak, as a slew of positive vaccine developments were announced. Stocks continued to show strength in the initial days of December trading, with the Dow Jones Industrial Average, S&P 500 and Nasdaq closing Friday’s session at a record high.
The Dow and S&P 500 fell Monday, while the Nasdaq advanced 0.5% and closed at another record high. Stocks opened modestly lower Tuesday.
The head of the Trump administration’s vaccine development effort, Dr. Moncef Slaoui, has said he believes the entire U.S. population could be inoculated by June. He predicted the country “should have this pandemic under control in the second half of 2021” if enough Americans receive the vaccine.
Cramer’s comments Tuesday come shortly after the Food and Drug Administration released documents stating it believes trial data for the Covid-19 vaccine developed by Pfizer and German partner BioNTech is consistent with criteria to be approved for emergency use authorization. The regulatory agency, meeting on the application Thursday, is expected to decide within days whether it will authorize the vaccine.
Massachusetts-based biotech firm Moderna also has applied for emergency use with the FDA, and the agency is set to meet on that one next week. Another company working on a vaccine, Johnson & Johnson, said Tuesday it expects to have late-stage trial results by January, which is earlier than it had expected.
Cramer said he believes that adding J&J’s vaccine to the mix would significantly increase the number of Americans who can be vaccinated. That, in turn, would accelerate the economic recovery timeline and make sectors that have been particularly hard hit by the pandemic such as travel more attractive for investors, he said. The “Mad Money” host said Tuesday he was recruited for J&J’s trial recently but he’s not participating.
“You’ve got to go buy the airline stocks. Now we know why the cruise lines are going up. You can go back to the American Expresses of the world,” Cramer said. “You could say..., ‘A lot of these have already moved,’ but you know what, there are plenty of people who did not expect this all to come together so quickly. The vaccine glut is the story of 2021.”
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
Видео Jim Cramer says he was recruited for Johnson & Johnson Covid-19 vaccine trial last week канала CNBC Television
CNBC’s Jim Cramer said Tuesday that Wall Street is gaining confidence in the potential rollout of a coronavirus vaccine in the U.S., suggesting investors believe the serious challenges caused by the pandemic could soon be behind the country.
“The market is very prescient. I think the market has been going up because we’re starting to realize this may be — for all intents and purposes in America, not in the rest of the world — over in the second quarter of 2021,” Cramer said on “Squawk on the Street.”
The stock market had a very strong November, despite uncertainty caused by President Donald Trump’s challenges to the election and a worsening Covid-19 outbreak, as a slew of positive vaccine developments were announced. Stocks continued to show strength in the initial days of December trading, with the Dow Jones Industrial Average, S&P 500 and Nasdaq closing Friday’s session at a record high.
The Dow and S&P 500 fell Monday, while the Nasdaq advanced 0.5% and closed at another record high. Stocks opened modestly lower Tuesday.
The head of the Trump administration’s vaccine development effort, Dr. Moncef Slaoui, has said he believes the entire U.S. population could be inoculated by June. He predicted the country “should have this pandemic under control in the second half of 2021” if enough Americans receive the vaccine.
Cramer’s comments Tuesday come shortly after the Food and Drug Administration released documents stating it believes trial data for the Covid-19 vaccine developed by Pfizer and German partner BioNTech is consistent with criteria to be approved for emergency use authorization. The regulatory agency, meeting on the application Thursday, is expected to decide within days whether it will authorize the vaccine.
Massachusetts-based biotech firm Moderna also has applied for emergency use with the FDA, and the agency is set to meet on that one next week. Another company working on a vaccine, Johnson & Johnson, said Tuesday it expects to have late-stage trial results by January, which is earlier than it had expected.
Cramer said he believes that adding J&J’s vaccine to the mix would significantly increase the number of Americans who can be vaccinated. That, in turn, would accelerate the economic recovery timeline and make sectors that have been particularly hard hit by the pandemic such as travel more attractive for investors, he said. The “Mad Money” host said Tuesday he was recruited for J&J’s trial recently but he’s not participating.
“You’ve got to go buy the airline stocks. Now we know why the cruise lines are going up. You can go back to the American Expresses of the world,” Cramer said. “You could say..., ‘A lot of these have already moved,’ but you know what, there are plenty of people who did not expect this all to come together so quickly. The vaccine glut is the story of 2021.”
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
Видео Jim Cramer says he was recruited for Johnson & Johnson Covid-19 vaccine trial last week канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
WATCH LIVE: New York Gov. Cuomo holds a briefing as state prepares for Covid vaccine — 12/11/2020How Costco Became A Massive "Members Only" RetailerJim Cramer breaks down stocks that young investors are buyingWhy Loup Ventures' Gene Munster says to be more selective about which FAANG stocks you ownWATCH LIVE: World Health Organization holds press conference on the coronavirus outbreak — 12/11/20Explained | The Stock Market | FULL EPISODE | NetflixInside the Lab That Invented the COVID-19 VaccineTwo IPO veterans on what could be next for DoorDash and AirbnbPfizer board member Gottlieb on FDA's move toward emergency approvalCramer on the 'K' recovery the U.S. is experiencing amid the pandemicCoalition Mounts Against Texas Election Lawsuit | Morning Joe | MSNBCHow the coronavirus pandemic is impacting retail sales and the economyThe Wild $50M Ride of the Flash Crash TraderPhysician on FDA advisory board explains her decision to vote against Pfizer vaccineJim Cramer: Return of individual investors changed the entire character of the marketCramer: Pent-up demand to define the next leg of the bull marketDr. Peter Hotez: The Covid Vaccine Discovery Was Not A 4 Month Process, It Was A 17 Year ProcessDistributing the COVID Vaccine: The Greatest Logistics Challenge EverCramer: We have a 'broken' IPO pricing systemGovernment shutdown looms as midnight deadline approaches